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had no impact on appetite during the short dwells of 30 and 120Acute effects of peritoneal dialysis solutions on appetite in
minutes. The demonstrated differences between the differentnon-uremic rats.
solutions appear to be due to different concentrations, and type,Background. Standard peritoneal dialysis (PD) solutions may
of nutrients used as osmotic agent (glucose, amino acids, ico-contribute to anorexia in PD patients due to the peritoneal
dextrin) or buffer (lactate), although differences in dialysateabsorption of glucose from the dialysate, abdominal discomfort
pH, tonicity and concentration of glucose degradation productsand other factors. New PD solutions containing alternative os-
also may be important. The present studies suggest a possiblemotic agents, neutral pH and bicarbonate as buffer were re-
positive effect on appetite by using bicarbonate/lactate buf-cently developed. To test the effect of these solutions on appe-
fered solutions instead of lactate buffered solutions.tite, we investigated how intraoral (IO) intake of sucrose via
an IO cannula was influenced by intraperitoneal (IP) infusion
of different PD solutions in an appetite model in rats.
Methods. The IO intake was measured in male Wistar rats Anorexia is a common complication that contributesafter an IP dwell of 30 and 120 minutes with the following PD
to protein-energy malnutrition and thereby may increasesolutions: 1.36%, 2.27% and 3.86% glucose based and lactate
morbidity and mortality in continuous ambulatory peri-buffered solutions (D); 1.36%, 2.27% and 3.86% glucose based
and bicarbonate/lactate buffered solutions (P); 7.5% icodextrin toneal dialysis (CAPD) patients. Several factors may con-
based solution (E); 1.1% amino acid-based solution (N); and, tribute to anorexia in CAPD patients such as uremic toxic-
2.5% glucose-based lactate-buffered solution (GB), using sham ity, unpalatable diets, complicating illnesses, reducedinjection (injection without infusion) as control. Prior to the
gastrointestinal motility, medication, inflammation andtests, rats were provided with an IO cannula, and were trained
various complications such as peritonitis [1, 2]. However,for two weeks until the rate of IO intake had stabilized.
Results. The D and N solutions inhibited IO intake. For the the peritoneal dialysis (PD) procedure as such also may
D solutions, the degree of appetite suppression was higher with influence ingestive behavior by causing abdominal dis-
the higher concentration of glucose. P 3.86%, but not P 1.36% comfort, by absorption of the osmotic agent and other
and P 2.27% solutions, inhibited the IO intake. However, a
factors [3]. Appetite is regulated by multiple controlcomparison of the degree of appetite inhibition between D
mechanisms with potential sites of regulation includingand P showed less inhibition with P 1.36%, 2.27% and 3.86%
the brain, the gastrointestinal tract and the liver [4].solutions than with corresponding D solutions. The E solution
did not seem to suppress appetite. Finally, no significant differ- Because food intake regulates appetite and post-absorp-
ence in IO intake was found between rats given GB 2.5% and tive metabolism modulates food intake [5], it may be
D 2.27%. expected that absorption of different nutrients from PDConclusions. In this appetite model in rats, the measurement
solutions has an impact on appetite in CAPD patients.of IO intake after the IP infusion of different dialysis solutions
The standard PD solutions used today contain unphys-showed that (1) N and D solutions may reduce appetite, and for
the D solutions the degree of appetite inhibition was related to iological concentrations of glucose and lactate. Various
the dialysate concentrations of glucose; (2) the P solutions had types of experiments in vitro or in vivo have demon-
less impact on appetite than the D solutions; (3) the E solution strated bioincompatibility of conventional PD solutions.
These solutions exert their cytotoxic effects through their
hyperosmolarity, high concentrations of glucose and lac-Key words: osmotic agents, lactate, bicarbonate, dialysate solutions,
anorexia, glucose, malnutrition. tate, low pH and the presence of glucose degradation
products [6, 7]. On the other hand, newer PD solutionsReceived for publication November 13, 2000
have recently been designed to improve the biocompati-and in revised form July 9, 2001
Accepted for publication July 25, 2001 bility, ultrafiltration capacity and nutritional effects of
the solutions via changes in pH, osmotic agents and the 2001 by the International Society of Nephrology
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buffer system. The use of bicarbonate, the natural buff- den]. The intraoral cannulation was carried out as fol-
lows. The rats were placed in a stereotaxis frame and anering system, has been suggested as a logical way to
create a pH neutral and more physiologic solution formu- incision was made in the midline of the scalp. Three
screws were fixed in the skull. A 5 cm long PE-100 tubinglation [8], and the use of a two or three-chambered bag
during heat sterilization also limits the generation of was then placed between the cheek and gum at a point
slightly anterolateral to the first upper molar on the sideglucose degradation products [9]. Furthermore, loss of
ultrafiltration capacity due to rapid absorption of glu- of the mouth. The tube was advanced subcutaneously
and the distal end of the tubing protruded above thecose, and the possible harmful effects of hypertonic glu-
cose solution on the peritoneal membrane make it im- surface of the skull, and a 9 mm piece of stainless steel
tubing was inserted within the roof of the mouth betweenportant to find effective alternative osmotic agents. The
availability of a solution based on glucose polymers (ico- the cheek and gum. Dental cement was used to cover
and fix the area between the screws and cannula. Thedextrin) allows the clinician to improve ultrafiltration in
both CAPD and automatic peritoneal dialysis (APD) animals were allowed three weeks of recovery after sur-
gery. The experimental study was approved by the Ani-patients during long dwells. Owing to the reduced carbo-
hydrate load, icodextrin also may offer long-term meta- mal Ethical Committee of the Karolinska Institute at
Huddinge Hospital.bolic advantages compared with glucose-based PD solu-
tions [10]. Amino acid-based PD solutions may improve
Measurement of ingestive behaviorprotein nutritional status, particularly in malnourished
PD patients. Amino acid-based solutions also may be Prior to the formal experiment, the rats were given a
series of training for two weeks initially until the rate ofmore biocompatible than glucose based solutions [11].
Hypophagia induced by PD solutions, due to the effect intraoral intake had stabilized. Pellets were removed at
07.00 hours and replaced after testing. The animals wereof absorbed nutrients from the solutions, has been re-
ported by our group and others [12, 13]. The inhibition tested for sucrose ingestion at 13.00 hours (one hour
after the strong lights were switched off, but using indi-of eating behavior caused by PD solutions may be spe-
cific to each nutritional constituent, and not simply an rect weak light for observation of the test). During the
test, the animals were placed in a circular (35 cm diame-effect of hyperosmolarity or large dialysate fill volume
[12, 13]. Ingestive behavior also might be impacted by ter) plexiglass arena and had their intraoral cannula con-
nected to a peristaltic pump (Alitea xv; Ventur Alitea,bioincompatibilities of PD solutions. Since new PD solu-
tions are different as regards biocompatibility and con- Stockholm, Sweden), which delivered 1 mol/L of sucrose
solution at infusion rate of 1 mL/min. This activity oftent of nutrients such as glucose, amino acids, icodextrin
and lactate, the effect of these PD solutions on eating ingestive behavior ends by the time when the animal
passively lets food drip from its mouth. The infusionbehavior may be different, too.
The above-mentioned studies indicate that different was then interrupted for 30 seconds before restart the
infusion. If the rats did not drip food out within onePD solutions may have an impact on ingestive behavior
due to absorption of nutrients and other factors in the minute, the infusion was continued and interrupted again
for 30 seconds when the animal dripped out the solution.solutions. To confirm this hypothesis, we tested intraoral
intake of rats in an experimental appetite model after This procedure was repeated until the criteria, that is,
the rejection of the solution within one minute after aintraperitoneal infusion of different commercial PD so-
lutions. 30 second interruption of the infusion, was fulfilled. The
rats could be used repeatedly for testing different solu-
tions. In a separate series of studies, we also investigated
METHODS
the effects of (1) no injection, (2) sham-injection (injec-
Experimental appetite model tion without infusion), and (3) injection of 30 mL of
bicarbonate buffered solution without glucose, on anMale Wistar rats (Mo¨llega˚rd breeding laboratories,
Ejby, Denmark) weighing 310 to 330 g, with free access intraoral (IO) intake. The IO intake did not differ be-
tween these procedures, indicating that injection andto water and pellets were maintained in individual cages
in air conditioned, temperature-controlled 22C colony infusion of volume as such had no significant impact on
appetite. Thus, no-injection or sham injection was usedrooms in which the lights were off between 12.00 and
24.00 hours, as darkness is important for the normal as control in the present study.
ingestive behavior in the rat. The methods have been
Peritoneal dialysis solutionsdescribed in detail previously [14].
Briefly, in this study, the rats were provided with an The following PD solutions were tested: D solutions
(containing 1.36%, 2.27% or 3.86% glucose, lactateintraoral cannula as described below. All surgery was
performed under pentobarbital anesthesia [60 mg/kg in- 40 mmol/L, pH 5.5); P solutions (two-compartment bag,
containing 1.36%, 2.27% or 3.86% glucose, mixture oftraperitoneal (IP); Mebumal, Nordic, Stockholm, Swe-
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Table 2. Effect of an IP dwell with 30 mL of 1.36%, 2.27% andTable 1. Characteristics of different commercial
peritoneal dialysis (PD) solutions 3.86% D solutions on intraoral intake (mL of sucrose, 1 mol/L)
after different dwell times
Lactate Bicarbonate
PD Osmotic agent Osmolality Dwell time D 1.36% D 2.27% D 3.86% Control
fluid g/dL mmol/L mosm/L pH
30 min (N8) 18.22.6a 17.42.6b 16.62.2b 22.02.3
D 1.36% glucose 40 0 344 5.5 120 min (N8) 19.13.6a 18.12.8a 14.94.4b 22.02.7
2.27% glucose 40 0 395 5.5
Data are mean  SD.3.86% glucose 40 0 483 5.5
a Compared to control P  0.05P 1.36% glucose 15 25 344 7.4
b Compared to control P  0.012.27% glucose 15 25 395 7.4
3.86% glucose 15 25 483 7.4
N 1.1% amino acids 40 0 365 6.6
E 7.5% polyglucose 40 0 284 5.6
Table 3. Effect of an IP dwell with 30 mL of 1.36%, 2.27% andGB 2.5% glucose 40 0 408 6.0
3.86% P solutions on intraoral intake (mL of sucrose, 1 mol/L)
after different dwell times
Dwell time P 1.36% P 2.27% P 3.86% Control
30 min (N8) 22.33.8a 20.72.7a 19.03b 22.24.6
120 min (N8) 22.64.1a 20.42.1a 19.12.2b 22.02.4lactate 15 mmol/L and bicarbonate 25 mmol/L, pH 7.4);
Data are mean  SD.N solution (1.1% amino acids, lactate 40 mmol/L, pH 6.6); a Compared to control P  0.05
E solution (7.5% icodextrin, lactate 40 mmol/L, pH 5.6) b Compared to control P  0.05
and GB solution (three compartment bag, containing 2.5%
glucose, lactate 38.8 to 40.8 mmol/L, pH 6.0) as shown in
Table 1. For these PD solutions, the compositions of buf- given E solution and sham injection, respectively, and
fer are sodium 132 mmol/L, calcium 1.25 mmol/L, magne- tested in random order on two consecutive days.
sium 0.25 mmol/L, and chloride 96 mmol/L. Effects of GB and D solutions on appetite. Twenty
rats were randomly divided into two groups (30 min
Experimental procedure group and 120 min group). The rats (N  10 in each
group) were treated with the 2.5% GB and 2.27% DIn the following experiments, the intraoral intakes of
solution, respectively, and tested in random order on1 mol/L of sucrose with the infusion speed of 1 mL/min
two consecutive days. The intraoral intake of no-injec-were measured in one group of rats at 30 minutes and
tion (pre-test) was used as control.in another group of rats at 120 minutes after the IP
infusion of 30 mL of the PD solution. In the experiments,
Analysis of dataeither sham injection or no-injection (pre-test) was used
The results were expressed as mean  SD and wereas controls in the separate investigations.
analyzed using the unpaired t test or paired t test whenEffects of different glucose concentrations of D solu-
ANOVA test showed significance (P  0.05) with thetions on appetite. Sixteen rats were randomly divided
aid of the Statview (SAS Institute, Inc., Cary, NC, USA)into two groups (30 min group and 120 min group). The
for a personal computer.rats (N  8 in each group) were given an IP infusion of
To compare the effect of D and P solutions, the degreeD solutions 1.36%, 2.27%, and 3.86% glucose, and sham-
of appetite inhibition using these solutions was calcu-
injection (no infusion) respectively, and tested in random lated by the formula:
order on four consecutive days.
Percentage of appetite inhibition (PAI %)Effects of different glucose concentrations of P solu-
tions on appetite. Sixteen rats were randomly divided  (pre-test intake  post-test intake)/
into two groups (30 min group and 120 min group). The
pre-test intake  100. (Eq. 1)rats (N  8 in each group) received IP infusion with P
solutions 1.36%, 2.27%, and 3.86% glucose, and sham-
injection (no infusion), respectively, and tested in ran- RESULTS
dom order on four consecutive days. The conventional lactate-buffered glucose-based D so-
Effects of N solution on appetite. Sixteen rats were lution significantly suppressed the intraoral intake of su-
randomly divided into two groups (30 min group and crose in comparison to controls after 30 minutes and
120 min group). The rats (N  8 in each group) were after 120 minutes (Table 2). The degree of appetite inhi-
given N solution and sham injection respectively, and bition was higher with the higher concentration of glu-
tested in random order on two consecutive days. cose (Table 2). In contrast, there were no significant
Effects of E solution on appetite. Sixteen rats were differences in IO intake between the bicarbonate buf-
randomly divided into two groups (30 min group and fered 1.36% or 2.27% P solutions and controls at 30 and
120 minutes after the IP infusion (Table 3); however,120 min group). The rats (N  8 in each group) were
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Fig. 2. Effect of N solution on appetite. The amino acid-based N solu-
tion significantly inhibited the intraoral intake both at 30 and 120 min-
utes (P  0.05). Abbreviations are: Control 30, control 30 min (sham-
injection); N 30, N solution 30 min; Control 120, control 120 minutes
(sham-injection); and N 120, N solution 120 minutes.
Fig. 1. Appetite inhibition caused by lactate buffered D and bicarbon-
ate/lactate buffered P solutions. Appetite inhibition following an intra-
peritoneal (IP) dwell 30 mL of D () and P () solutions was studied
after 30 minutes (A) and 120 min (B). The percentage of appetite
inhibition (PAI %) was calculated as the pre-test minus post-test in-
traoral intake relative to pre-test intake (100). There were significant
differences in PAI % between D and P for 1.36%, 2.27% and 3.86%
solutions, respectively (P  0.05).
Fig. 3. Effect of E solution on appetite. The intraoral intake in the
icodextrin-based E solution group was similar to the control group
(sham-injection), and no significant differences were found between 30
and 120 minutes. The numbers 30 and 120 on the horizontal axis denote
the number of minutes.3.86% P solution significantly reduced intraoral intake
at 30 and 120 minutes (Table 3).
A separate comparison of D and P solution showed
that the percentage of appetite inhibition was more and although the effect on appetite inhibition with GB
marked with D solution (17.3%,21% and25% for solution 2.5% tended to be less than with D 2.27% solu-
D solutions 1.36%, 2.27% and 3.86%, respectively) than tion, there was no significant difference between the two
with P solutions (0.5%,6.8% and14.4% for P solu- solutions (Fig. 4).
tions 1.36%, 2.27% and 3.86%, respectively) at 30 min-
utes of dwell time (Fig. 1A). The corresponding data at
DISCUSSION120 minutes of dwell time (Fig. 1B) were13%,17.8%
and 32.3% for D solution 1.36%, 2.27% and 3.86%, For the past years, the depletion–repletion model has
respectively, and2.7%,7.3%, and13.2% for P solu- dominated the study of food intake. This model proposes
tion 1.36%, 2.27% and 3.86%, respectively. These differ- that available nutritional substrates (for example, glu-
ences were statistically significant for the different con- cose, lipids and amino acids) are constantly monitored
centrations (P  0.05). with declining amounts triggering meal onset and that
The amino acid-based N solution significantly sup- the meal is terminated when substrates are sufficiently
pressed IO intake in comparison to the control at 30 and replenished [15]. The present experiments assessed in-
120 minutes of dwell time (Fig. 2). However, the 7.5% gestive behavior quantitatively by measuring the oral
icodextrin-based E solution exerted no significant appe- consumption of a carbohydrate solution after intraperi-
tite inhibition as compared with control at 30 and 120 toneal infusion of different PD solutions in conscious,
min after the infusion (Fig. 3). free-moving rats. This model has been used earlier in
neuropharmacological studies of appetite regulation andFinally, GB 2.5% solution also suppressed appetite
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and our data showed that D peritoneal dialysis solutions
suppressed appetite and that the degree of suppression
was in proportion to the dialysate concentration of glu-
cose. These results suggest that the high concentration
of glucose in the PD solutions is one factor determining
appetite inhibition. We also found that the P 1.36% and
2.27% solutions did not significantly inhibit intraoral in-
take, while P 3.86% solution inhibited appetite. It is
interesting that the percentage of appetite inhibition was
less with P than with D for each glucose concentration.
This effect might be due to a combination of factors such
as differences in lactate concentration, pH, and glucose
degradation products, although more advanced studies
are still needed to confirm the mechanism.
Fig. 4. Effects of GB and D solutions on appetite. There were no
Absorption of nutrients as well as utilization of ab-significant differences between the 2.5% glucose-based and lactate-
buffered (GB) solution and the 2.27% glucose-based and lactate-buf- sorbed nutrients from PD solutions may regulate food
fered D solution. Both of the solutions significantly inhibited intraoral intake [22]. Lactate is easily reabsorbed into the blood
intake when compared to the control (P 0.05). Abbreviations of control
and carried to the liver, where it is oxidized to pyruvate,30 min (pre-test; no injection), GB 30 min, D 30 min, control 120 min
(pre-test; no injection), GB 120 min and D 120 min are respectively Control and pyruvate is then converted into glucose by the gluco-
30, GB 30, D30, Control 120, GB 120 and D120 on the horizontal axis. neogenic pathway in liver. The metabolism of nutrients
such as lactate, pyruvate and glucose in the liver may
influence food intake in various way [23, 24]. Oxidation
of pyruvate by mitochondrial pyruvate dehydrogenasehas proven to be accurate and highly reproducible, al-
provides reducing equivalents for the respiratory chain,lowing the same group of animals to be studied repeat-
and it is possible that the generation of reducing equiva-edly on consecutive days. A training and adaptive period
lents in the mitochondria may be the common featureare required during which the intake of the orally infused
of the hypophagic effects of these metabolites [25]. Insolution is gradually increased until a stable intake level
addition, hormonal signals generated by the gastrointes-is attained [14, 16].
tinal tract are sensed directly by the brain so that changes
Bicarbonate/lactate buffered solution in appetite and food intake occur. Thus, satiety is a result
of elevated levels of specific circulating nutrients andThe impact of lactate buffered solutions on cell func-
gastrointestinal signals [26]. Metabolites, which are di-tion has been assessed in many in vitro and ex vivo
rectly oxidized by enzymes bound to the mitochondriasystems, but, despite significant in vitro and ex vivo data
membrane, also affect feeding. The oxidation of injectedindicating its bioincompatibility, lactate-buffered PD so-
metabolites may add to the dynamic process of interme-lutions have been used almost exclusively in PD [17, 18].
diate metabolism, and thus reduce the threshold at whichThe potential in vivo consequences of repeated exposure
post absorptive factors contribute to satiety. The rate ofto lactate buffered solutions have driven the develop-
energy (ATP) production, associated with the turnoverment and introduction of potentially more biocompatible
of metabolic fuels, is inversely related to feeding [27, 28].solutions with a subsequent reduction of the unphysio-
The role of satiety signals in the control of food intakelogical components of lactate-buffered PD fluids, such
is thought to occur in response to liver metabolism andas low pH, high concentrations of lactate, and glucose
hypothalamus secretion [29]. It is generally assumed thatdegradation products [19].
there are various types of cells that sense the presenceThe use of bicarbonate as buffer has made it possible
of specific nutrients (such as glucose, protein and lipid)to create a pH-neutral and more physiologic solution
or respond to their rate of metabolism or production offormulation [8]. The biocompatibility of bicarbonate buf-
specific metabolites (such as amino acids, lactate andfered solutions has been demonstrated to be better than
pyruvate), and that these cells are capable of signalinglactate-based solutions in both in vitro and ex vivo stud-
this information to the region of the brain that controlsies [20]. The two-chambered bag used for the bicarbon-
food intake [5, 26].ate/lactate solution also limits the generation of glucose
Furthermore, the bicarbonate/lactate buffered solu-degradation products during the heat sterilization [9].
tion has been shown to be associated with less infusionClinical studies have shown that the bicarbonate-buf-
pain than that of lactate buffered solution in PD patientsfered solution was well tolerated and clinically at least
[30]. This might also have contributed to the less inhibi-as efficacious as lactate buffered solutions [21]. In the
tory effect of P solution on intraoral intake as comparedpresent study, we first tested the effect of conventional
D peritoneal dialysis solutions on the food intake in rats, to D solution in the present study.
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Amino acid-based solution loidal properties, a 7.5% icodextrin solution exerts an os-
motic pressure of only 284 mOsm/L; furthermore, theThe amino acid-based N solution was introduced with
concentration of glucose degradation products (GDPs)the dual purpose of providing an alternative osmotic
in this solution is very low in comparison to that of stan-agent and giving supplementary protein to patients with
dard glucose based solutions [37]. In the present study,protein malnutrition. The amino acids’ supply from di-
no significant reduction of IO intake was found whenetary protein may influence brain metabolism by provid-
icodextrin was given IP. It is possible that the normaling specific amino acids, which are precursors of major
osmolality, lower content of GDPs, and the slow processneurotransmitters [31]. It has been proposed that amino
of absorption and metabolism of icodextrin contributedacids act as significant components of the control mecha-
to these results. However, a possible appetite inhibitorynism for protein and energy intake by inducing appetite
effect after a dwell time longer than 120 minutes cannotsuppression through their effect on neurotransmitter
be excluded.synthesis. In this study, the intraperitoneal administra-
tion of N solution, containing 1.1% amino acids, was
Glucose degradation productsfound to significantly inhibit carbohydrate intake after
Glucose degradation products (GDPs) develop in glu-a 30 and 120 minute dwell.
cose-based peritoneal dialysis fluids during heat steriliza-It has been suggested that protein intake is physiologi-
tion and storage [38, 39]. GDPs in PD solutions maycally regulated by amino acids accumulating after a meal.
cause clinically significant abdominal pain or discomfortThe inhibitory effect of amino acids on feeding is medi-
during infusion and may therefore affect food intake.ated by the liver, neurotransmitters, and receptors in the
However, the present study could not demonstrate acentral nervous system [32]. In rats taking a pure protein
significant difference between GB 2.5% (which containsdiet, inhibition of ingestion after a protein meal declines
a significantly reduced amount of GDPs) and the Dwith time in proportion to the plasma concentration of
2.27% solution. We do not know the exact mechanismsvarious amino acids. Moreover, there are endogenous
of this unexpected result. The same high lactate concen-satiety factors that are secreted in response to a meal.
tration, the unphysiological pH and the slightly higherThe best known of these are cholecystokinin, insulin and
glucose concentration in GB solution than in D solution,insulin like growth factor-1 (IGF-1), but several other
or a combination of these factors may have contributedpeptides and cytokines such as leptin, gastric releasing
to the lack of differences.peptide, glucagon and tumor necrosis factor-	 have been
In summary, these studies demonstrate that differentdemonstrated to affect appetite [33, 34]. They may inhibit
peritoneal dialysis solutions have different acute effectsgastric motility and signaling to the central nervous sys-
on appetite, as assessed by this experimental appetitetem via peripheral nerves (vagal afferent fibers), as well
model in the non-uremic rat. The concentration andas through receptors within the nucleus of the solitary
properties of nutrients (glucose, amino acids and lactate)tract in the brainstem area, where the satiety signals are
in the solutions seem to play a key role in the regulationintegrated with afferent signals from the tongue and the
of appetite. The icodextrin-based solution did not affectgastrointestinal system [15, 35]. The above-mentioned
appetite during these short-term experiments; however,pathways for appetite control may perhaps explain why
due to the slow absorption of icodextrin, appetite inhibi-the amino acid-based PD solution injected intraperitone-
tion after a long dwell cannot be excluded. In additionally in rats was found to inhibit carbohydrate intake in
to the absorption of nutrients from the dialysate, otherthe present study.
factors such as low pH, hypertonicity and glucose degra-
Icodextrin based solution dation products also may be important. Furthermore, it
should be noted that many factors apart from peritonealFor the long dwell in PD, glucose based solutions are
dialysis solutions, such as uremia and concurrent illness,not optimal because of the rapid absorption of glucose,
are involved in the complex process of appetite regula-which results in a short duration of net ultrafiltration. In
tion in uremic patients. Therefore, the clinical relevanceaddition, glucose has been implicated in the glycation of
of these experimental results is not clear. Nevertheless,proteins in the peritoneal membrane, resulting in diabeti-
the present studies indicate a possible beneficial effectform changes that can lead to further deterioration in
on appetite when using bicarbonate/lactate buffered so-membrane properties [36]. Therefore, there is a need
lutions instead of lactate buffered solutions, and possibly,for alternative osmotic agents that would enable a more
when using the icodextrin based solution, whereas thephysiological solution to be used during longer dwell
amino acids-based solution offers no advantage in thisperiods that have fewer metabolic complications.
respect. Clinical studies of new PD solutions or combina-The osmotic effectiveness of glucose polymers is now
tions of the three new solutions should evaluate a possi-well established and icodextrin is the first colloid osmotic
agent used in commercial PD solutions. Owing to its col- ble impact on appetite and food intake.
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